Binoid vs. Delta Extrax: Two Δ8 Storefronts, Judged on the Maps They Publish

Two national storefronts. One country. Two materially different maps of it.

Binoid and Delta Extrax both sell Δ8 and adjacent cannabinoids by mail, and both do what this category’s better operators do: publish a list of states they will not ship to. Laid over each other, the lists agree on nine states and disagree on fourteen. Not a scandal — just an honest picture of how much of this geography is a judgment call.

So this compares no cartridge contents. We have no laboratory. It compares the two documents a buyer can read before spending money: the lab-results index and the restricted-state list.

The two dossiers

What each company publishes, per its own pages in late August 2026

Binoid — COAs	Grouped by product category and cannabinoid type, with distillate blocks labelled 2022–2024; also hosts COAs for stocked third-party brands including CBDfx, Koi and Urb
Binoid — map	Δ products withheld from six states: CA, OR, AK, WV, WA, CO. THC-A withheld separately from twelve: AR, HI, ID, KS, LA, OK, OR, RI, UT, VT, WA, WV
Extrax — COAs	Listed per product and variant against batch codes; the page says products undergo third-party testing but names no laboratory
Extrax — map	One flat list of seventeen: AK, AZ, CA, CO, DE, IA, ID, MS, MT, ND, NV, NY, OR, RI, UT, VT, WA

The lab-sheet test

Every review here starts in one place: how much work is it to reach the certificate of analysis — the batch lab report — for the thing in your cart?

Both pass, in different registers. Binoid’s lab-results page is browsable: reports sit in labelled groups you can scroll, no support email required.

Extrax’s lab-test page organises the other way — by category, then product line, then variant against a batch code. That forces the check a COA exists for: batch on the report against batch on the package. It is also more demanding: you need your flavour and code before the page helps.

Then the shared weakness. Neither page we read names the laboratory behind its reports, or that lab’s accreditation — the outside audit of a lab’s methods. Without it a COA says what somebody measured and little about the somebody. That gap matters most for converted cannabinoids, where the rows worth reading are residual solvents and conversion byproducts, and an unnamed lab’s methods do the work.

The maps, laid over each other

Nine states sit on both lists: Alaska, California, Colorado, Idaho, Oregon, Rhode Island, Utah, Vermont and Washington. Call that the consensus. Outside it the divergence is wide — eight states Extrax refuses, Arizona and New York among them, appear on neither Binoid list, and six Binoid withholds from, Kansas and West Virginia included, are absent from Extrax’s.

Credit to both on structure. Binoid splits restrictions by product class, treating Δ-series and THC-A separately, which is closer to how state rules actually differ. Extrax’s flat list is blunter but readable at a glance, and it sits on the shipping policy rather than at the foot of a lab page.

Neither is a legal opinion. A shipping list is a company’s risk posture — counsel, carriers, payment processing and appetite, in proportions nobody publishes. Two lists this different are the proof.

The state neither map names

Texas appears on no list on either site as of late August.

Per the Texas Tribune’s 10 August report, Texas banned several hemp-derived THC products at the end of July — delta-8, delta-10, THCP and THCA flower among them, under a Schedule I classification — and U.S. District Judge Jeffrey Brown declined an emergency request to pause it, finding the industry had not shown irreparable harm. A preliminary-injunction request remained pending. We will not guess how that ends.

The lesson does not depend on the outcome. A state’s absence from a seller’s list is not a finding that anything is permitted there; it means the seller has not listed it. Your own bucket on the state patchwork governs your cart. A checkout page does not, and neither do we.

The marketplace wrinkle

Both increasingly sell other people’s brands — Binoid’s index carries reports for stocked third-party lines, the 3Chi catalogue we assessed separately among them, and Extrax runs a marketplace beside its house products. For shoppers that is range. For paperwork it is a longer chain: a retailer publishing a report it did not commission, for a batch it did not make, from a lab it does not name.

One boundary belongs on this map as much as the state lines: nothing either company sells has been evaluated by the FDA, we describe no effects and recommend no quantities, and the shelf is adults 21 and over, where your state allows it.

The ledger

The honest ledger

Pros

Binoid: a genuinely browsable COA index — grouped, scrollable, no support email needed
Binoid: restrictions split by product class, mirroring how state rules actually diverge
Extrax: reports pinned to product, variant and batch code, forcing the batch match
Extrax: one flat map on the shipping policy, plus age and fraud verification on every order

Cons

Neither index names its testing laboratory or that lab's accreditation — the most useful line either page could add
The two maps disagree on fourteen states — much of this geography is commercial judgment, not settled ground
Neither names Texas, where the state banned delta-8, delta-10, THCP and THCA flower at the end of July per Texas Tribune reporting — absence from a list is not permission
Binoid's index carries distillate reports labelled 2022, 2023 and 2024; batch-current is the only kind of current a lab sheet has
Both resell other companies' brands, lengthening the paperwork chain without lengthening anyone's accountability

Verdict

Who is this for? Binoid suits the reader who browses lab work first and shops second; Extrax the reader who knows the product and wants the report for that run. Anyone reading a shipping list as a green light should skip both — lists that disagree on fourteen states answer no legal question, and yours starts with your own state.